Today: 21 May 2026
XRP price today: Ripple token holds $1.91 as Fed pause and White House crypto talks come into view
28 January 2026
2 mins read

XRP price today: Ripple token holds $1.91 as Fed pause and White House crypto talks come into view

New York, January 28, 2026, 17:02 (EST) — After-hours trading

  • XRP held close to $1.91, trading within a narrow range between $1.89 and $1.94.
  • The Fed left rates unchanged, leaving macro traders fixated on future moves in U.S. borrowing costs.
  • Washington faces its next hurdle with a White House meeting on crypto market regulations and stablecoins scheduled for Feb. 2.

XRP hovered near $1.91 late Wednesday, dipping roughly 0.3% in the past 24 hours after fluctuating between $1.89 and $1.94. Trading volume held steady, with $2.33 billion worth of XRP exchanged over the day, according to CoinMarketCap data.

That tight range still counts because traders are viewing XRP less as an isolated play and more as a rate-sensitive risk asset. Shifts in U.S. policy — whether from the Fed or Capitol Hill — have been jolting crypto sentiment in sudden waves.

The Federal Reserve kept interest rates unchanged on Wednesday, highlighting persistent inflation but providing scant clues on when rate cuts could restart. Tim Holland, chief investment officer at Orion, described the session as “a non-event,” leaving markets eager for a fresh spark. Reuters

In Washington, the White House has scheduled a meeting on Feb. 2 with top executives from banks and the crypto sector, aiming to break the deadlock over the Senate’s “Clarity Act,” according to three industry sources cited by Reuters. The core issue: whether crypto firms can pay interest or other incentives on dollar-pegged stablecoin holdings. Standard Chartered projects stablecoins could siphon off around $500 billion in deposits from U.S. banks by the end of 2028. Summer Mersinger, CEO of the Blockchain Association, said the group was “proud to participate,” while Digital Chamber CEO Cody Carbone praised the White House for “pulling all sides to the negotiating table.” Reuters

The legislative drive has extended into the SEC’s crypto task force circle. In a letter posted on the agency’s website, lawyer Teresa Goody Guillén sided with Ripple, arguing that frameworks considering a “passive economic interest” sufficient to activate securities laws risk confusing speculation with actual investor rights. SEC

Ripple, the firm best known for XRP, set a near-term date Wednesday: XRP Community Day is back on Feb. 11. The event will dive into regulated products, ETFs, and “wrapped” XRP — tokens that replicate XRP on other blockchains — plus talks on DeFi, covering blockchain lending and trading. Ripple

Traders are focused on price action. XRP keeps slipping back to the low-$1.90s, with the $2 mark looming as the next clear hurdle if it can gather momentum.

Crypto continues to carry a hefty policy and enforcement risk premium that can shift abruptly. Chainalysis reported that money launderers moved at least $82 billion in cryptocurrencies in 2025—a figure regulators frequently use to push for stricter regulations.

XRP still carries legal wounds from years of disputes over whether its token sales qualify as securities transactions. A U.S. judge ruled that XRP itself isn’t a security when traded blindly on secondary platforms—a ruling that’s been referenced in cases involving XRP-related products.

Traders are gearing up for Monday’s White House meeting, looking for clues on whether the Clarity Act will gain traction — and if the battle over stablecoin “rewards” will ease or escalate. Ripple’s Feb. 11 event looms as the next key moment on the XRP calendar, promising updates that might change the story, even if the price remains stuck.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Intuit stock price dips as AI fears circle TurboTax, but RBC sticks with $850 target
Previous Story

Intuit stock price dips as AI fears circle TurboTax, but RBC sticks with $850 target

Gold price today: Bullion pushes toward $5,400 as Fed decision fails to cool the rally
Next Story

Gold price today: Bullion pushes toward $5,400 as Fed decision fails to cool the rally

Go toTop